Fair-Value Report — Nexchip Semiconductor (02249.HK)

Insider Signal

Verified Snapshot

Business Overview

Nexchip Semiconductor Corporation (合肥晶合集成电路股份有限公司) is a Hefei, Anhui-based pure-play wafer foundry. Founded in 2015 as a joint venture between Hefei City Government's investment arm and Taiwan's Powerchip Technology Corporation, Nexchip has grown into China's third-largest pure-play foundry (after SMIC and Hua Hong), and ranks ninth globally by revenue (Frost & Sullivan, 2025).

Core business: Wafer fabrication services using mature process nodes (55nm, 40nm, 28nm). Nexchip holds the world's #1 position in display driver IC (DDIC) wafer foundry by market share. Revenue mix also includes CIS (CMOS image sensors), PMIC (power management ICs), Logic ICs, and MCUs. Wafer volume sold in 2025: 1,624.68K wafers, +18.88% YoY.

Technology roadmap: 28nm logic platform development is complete and customer tape-outs are underway. 22nm R&D is in progress (expected commercial ramp c. 2027–2028). The H-share IPO in July 2026 raised ~CNY 6.8B net, with 53.6% earmarked for 22nm R&D and 23.1% for AI-enabled manufacturing initiatives.

Ownership: Post-IPO, Hefei Construction Investment (合肥建投) remains the largest shareholder at approximately 39.7%. Huaqin Technology (华勤技术) holds ~10.00% in aggregate (A + H-shares combined). Powerchip Technology's stake was reduced when Huaqin acquired their block in August 2025 for CNY 2.39B.

AH listing structure: The A-share (688249.SH, listed on STAR Market since 2023) trades at approximately CNY 65–70 per share, implying an AH premium of about 110% (i.e., H-shares at HKD 34.59 ≈ CNY 32.07 represent a 55% discount). This is unusually wide by HK market standards and reflects: restricted A-share market access, momentum-driven A-share valuations, and limited awareness of the H-share listing.

Valuation

Method Selection

Nexchip is a profitable capital-intensive foundry in an expansion/build-out phase. For such companies: EV/EBITDA is the primary anchor metric (strips out D&A distortion of the investment cycle); P/Book provides a floor check (anchored by ROE vs. cost of equity); DCF serves as an intrinsic value cross-check despite limitations (high reinvestment burden, high debt, negative near-term FCF). Standard P/E is unreliable given the cyclical earnings compression in Q1 2026.

WACC Derivation (CNY terms)

Three-Scenario DCF (CNY millions; all shares, run via dcf.py)

Revenue base: CNY 10,885M (FY2025). Post-IPO diluted shares: 2,172M. Post-IPO net debt: CNY 17,070M. Tax: 15%. SBC: 0.5% of rev. Weights: 25% bull / 50% base / 25% bear.

Reverse DCF: What Does the H-Share Price Imply?

At HKD 34.59 (= CNY 32.07), total H-share market cap = CNY 69.66B; with CNY 17.07B net debt, the market-implied EV = CNY 86.73B.

Running the reverse DCF bisection solver (scripts/reverse_dcf.py) yields no solution — the market-implied EV exceeds the model ceiling even under the bull scenario's maximum achievable EV of ~CNY 28.8B. This means the market is implicitly using either:

• A dramatically lower WACC (approximately 5–7%), consistent with treating Nexchip as a quasi-sovereign strategic asset with implicit government backstop; or
• Revenue CAGR of 20%+ through 2035 combined with operating margins expanding to 22%+ — a TSMC-level scenario for a company that today earns 3.3% ROE.

At current H-share price, the market is pricing in an extraordinary convergence of sustained high growth AND dramatic margin improvement AND a low-risk-premium multiple. Any one of these elements failing to materialize leads to significant downside.

EV/EBITDA Peer Comparison

All market caps at H-share price for H-listed companies. Currency conversions: 1 USD = HKD 7.80 = CNY 7.24. Sources: HKEX filings, stockanalysis.com, company 2025 annual reports, HKEX market data (15–16 Jul 2026). Nexchip EBITDA estimated from operating cash flow data (operating CF/share = CNY 1.91 × pre-IPO A-share count = CNY 3,734M CF; estimated D&A = CNY 3,200–3,800M → EBITDA margin ~42–46%).

† EV/EBITDA shown for SMIC and Hua Hong are based on consensus forward estimates (NTM), as trailing figures are distorted by their new-fab ramp periods when D&A inflates ahead of yield/revenue. ‡ Hua Hong 2025 EBITDA margin is depressed by FAB9 (Wuxi phase 2) ramp. ‡‡ Nexchip EV/EBITDA trailing is estimated; forward (2026E) will be higher given Q1 2026 earnings compression — directionally the MOST expensive of the three on a through-cycle basis.

Peer conclusion: Nexchip's H-shares trade at a premium to peer median on trailing EV/EBITDA (28–34x vs 23.8x), contrary to the typical expectation that a smaller, less-proven foundry should trade at a discount. On P/E (trailing 2025), Nexchip looks cheaper (99x vs 140x SMIC), but SMIC's and Hua Hong's multiples reflect expected earnings recovery from current troughs, while Nexchip's trajectory is going the other direction in 2026. The fundamental peer premium is NOT justified by superior ROIC (3.3% vs WACC 10.2%) or superior growth (revenue CAGR similar across all three).

P/Book Cross-Check (Damodaran Justified P/B)

Damodaran's framework: Justified P/B = ROE / Cost of Equity. For Nexchip:

• ROE (2025): 3.3% | Cost of equity: 11.18%
• Justified P/B = 3.3% / 11.18% = 0.30x
• Book value/share (post-IPO estimate): approximately CNY 12.66 = HKD 13.67
• Justified price (P/B method): HKD 13.67 × 0.30 = HKD 4.10
• Current H-share price: HKD 34.59 → 3.3× price-to-book premium above what ROE fundamentally justifies

The P/B method confirms the DCF result: the stock is deeply overvalued relative to current earning power. The only justification is belief in a dramatic ROE improvement to WACC or above — which requires margin expansion to 18%+ operating margins and sustained high-ROIC capital allocation.

Conclusion & Rating

Rating: Hold

12-month target: HKD 29 (implied downside: −16%)

The target is derived primarily from a sector-relative EV/EBITDA approach at 13–15× 2025 EBITDA (a discount-to-peers multiple reflecting: Nexchip's smaller scale, lower relative technology maturity vs. SMIC, and near-term earnings headwinds), cross-checked with DCF bull case (HKD 5.83), and anchored against the current AH discount structure.

The case against buying at HKD 34.59:

• Q1 2026 net profit -62.6% is severe, and the drivers (ASP compression + D&A ramp) are structural in 2026
• ROE of 3.3% is below WACC of 10.2% — the company is destroying equity value in economic terms
• DCF base and bear cases show negative equity value due to the large net debt burden
• The stock is the MOST expensive of the China foundry trio on forward-adjusted EV/EBITDA
• Even the bull case DCF only yields CNY 5.40 vs the current CNY 32.07 price (HKD 5.83 vs HKD 34.59)

The case for holding (not selling aggressively):

• H-shares trade at a 55% discount to the A-share, providing structural downside protection relative to the A-share — if the AH gap narrows, H-share upside is significant
• China's strategic semiconductor policy (Made in China 2025 successors) creates a persistent premium for foundry names with government-backed shareholders (Hefei Investment ~40%)
• 22nm technology ramp (targeted 2027–2028) is a genuine option value if execution succeeds
• DDIC market leadership (globally #1 in display driver wafer foundry) provides a structural moat in a large end market
• IPO proceeds (CNY 6.3B net) strengthen the balance sheet and fund the technology transition

Signal real, price stretched. Huaqin's strategic buy is genuine conviction in the business — for industrial reasons. At HKD 34.59, existing H-share holders should hold given the AH discount floor and policy tailwinds, but initiating new positions at current prices requires accepting that you are paying for a dramatic ROIC recovery that is 2–3 years away, in an industry facing near-term pricing pressure. The margin of safety is thin. New money should wait for either a lower entry point (HKD 28–30 range) or evidence of Q2/Q3 2026 earnings stabilization.

Key Risks

• Earnings compression accelerates (HIGH): Q1 2026 showed -62.6% net profit decline. If ASP pressure in DDIC and CIS markets persists through H2 2026, the stock trades on 250–400x forward P/E — unsustainable.
• 22nm execution risk (MEDIUM): The bull case depends heavily on successful 22nm commercialization. SMIC has struggled for years at advanced nodes under US export controls. Nexchip faces the same EUV tooling restrictions.
• AH gap widening (MEDIUM): If China A-share sentiment deteriorates or capital controls tighten, the A-share could correct toward H-share prices rather than H-shares catching up — eliminating the floor argument.
• Debt servicing risk (MEDIUM): CNY 17B net debt at 3.75% = ~CNY 638M interest per year. In 2026, if net profit is only CNY 200–300M, interest coverage falls below 1x on a net income basis (though EBITDA coverage remains comfortable).
• Sector re-rating (MEDIUM): The China semiconductor sector is priced on policy/strategic premium multiples, not fundamentals. Any policy disappointment or China–US geopolitical escalation affecting supply chains could compress all foundry multiples.
• Huaqin lock-up overhang (LOW): As a strategic shareholder with a 6-month H-share lock-up post-IPO (likely through January 2027), Huaqin's shares will become tradable — modest overhang risk thereafter.

Sources

• HKEX Shareholding Disclosures — 香港华勤 equity change report for 688249, filed 10 Jul 2026 (CFi.cn mirror)
• Nexchip H-share Prospectus (02249.HK), published 30 Jun 2026 via HKEXnews
• Nexchip 2025 Annual Report (688249.SH), published 27 Mar 2026 — revenue, net profit, EPS, book value, operating CF
• Nexchip Q1 2026 Quarterly Report (688249.SH), published 24 Apr 2026 — earnings, revenue, margin data
• SMIC (0981.HK) 2025 financials — stockanalysis.com (verified 16 Jul 2026)
• Hua Hong Semi (1347.HK) 2025 financials — stockanalysis.com (verified 16 Jul 2026)
• IPO analysis: Minichart.com.sg, Caproasia.com, Bamboo Works — H-share listing details, IPO price, market cap
• China 10Y government bond yield: TradingEconomics.com / ChinaBond — 1.73% as of 14 Jul 2026
• Damodaran (NYU Stern) — Country Risk Premium (China 2.0%), Semiconductor Beta
• Valuation scripts: dcf.py, wacc.py, reverse_dcf.py (stock-valuation skill)